Phase 3 trials have now initiated for overweight and obesity at this point, assessing CagriSema in larger numbers and for longer periods of time. References: Frias JP, et al
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
This article explains general peptide reconstitution principles, UK regulatory status, and critical safety considerations it does not constitute clinical advice or endorse self-administration
Most available data comes from early-stage or limited clinical studies, which describe how these peptides affect biological pathways rather than long-term outcomes
Clinical trials have used doses of 25-30 nmol/kg by IV infusion (Schneider-Helmert et al., 1981Subcutaneous administration and oral intestinal absorption have also been studied
RNA isolation and quantitative RT-PCR Total RNA from cells was isolated with Trizol reagent (Qiagen GmbH, Hilden, Germany) and RT-PCR was conducted using a quantitative SYBR Green RT-PCR kit (Applied Biosystems, Warrington, UK) was used with a Step One Plus RT-PCR System (Applied Biosystems)